Global Human Milk Oligosaccharides (HMOs) Market Outlook, 2031

The global human milk oligosaccharides (HMOs) market has emerged as a dynamic and rapidly evolving segment within the functional ingredients industry, providing complex carbohydrates naturally found in human breast milk that offer significant health benefits for infants and adults. HMOs are the third most abundant solid component in human milk after lactose and fat, playing a crucial role in establishing the infant gut microbiome, supporting immune system development, and protecting against pathogens. The market encompasses a range of HMO compounds including 2'-fucosyllactose (2'-FL), lacto-N-neotetraose (LNnT), and other oligosaccharides that are increasingly produced through biotechnological fermentation processes for commercial applications. The market is driven by the growing awareness of the health benefits of HMOs, the increasing demand for premium infant formula products that mimic the nutritional profile of breast milk, and the expanding application of HMOs in dietary supplements and functional foods for adult health.

According to the research report "Global Human Milk Oligosaccharides (HMOs) Market Outlook, 2031," published by Bonafide Research, the global Human Milk Oligosaccharides (HMOs) market was valued at USD 200 Million in 2025. The market is experiencing substantial transformation driven by technological advancements in HMO production, expanding regulatory approvals, and the growing application scope beyond infant nutrition. The shift toward clean label and natural ingredients in food and beverage products is creating opportunities for HMOs as functional ingredients in adult nutrition products. The rising consumer awareness of the gut-brain axis and the role of the microbiome in overall health is driving demand for HMO-containing dietary supplements and functional foods. Manufacturers are increasingly investing in research and development to identify new HMO compounds, develop cost-effective production methods, and expand application opportunities.

Drivers Growing demand for premium infant formula and early-life nutrition: The increasing demand for premium infant formula products that mimic the nutritional composition of breast milk is a primary driver for the HMOs market. Parents seeking optimal nutrition for their infants are driving demand for formula products containing HMOs, which support immune development and establish healthy gut microbiomes.

Rising awareness of gut health benefits and immune support: Growing scientific evidence demonstrating the benefits of HMOs for gut microbiome modulation, immune function, and protection against pathogens is driving consumer interest in HMO-containing products. The expanding application of HMOs in dietary supplements and functional foods for adults is creating new market opportunities.

Challenges High production costs and complex manufacturing processes: HMO production through biotechnological fermentation requires significant investment in manufacturing infrastructure, specialized expertise, and quality control systems. The complexity and cost of production limit the number of suppliers and contribute to premium pricing for HMO-containing products.



Regulatory approval requirements and safety assessments: HMOs are subject to regulatory approval as novel food ingredients or food additives in various regions, requiring extensive safety assessments and clinical evidence. The regulatory approval process is time-consuming and costly, potentially delaying product launches and market entry.

Trends Expansion of HMO applications beyond infant formula: Manufacturers are increasingly exploring applications for HMOs in dietary supplements, functional foods and beverages, and adult nutrition products. The growing body of scientific evidence demonstrating health benefits for adults is driving product development in these emerging application areas.

Development of novel HMO compounds and production methods: Research and development efforts are focused on identifying new HMO compounds with unique health benefits, developing cost-effective production methods, and creating HMO blends that mimic the diversity of human breast milk. Advances in biotechnology and fermentation processes are enabling production of increasingly complex HMO structures.

The market is segmented by application into dietary supplements, functional food and beverages, infant formula, and others, with infant formula representing the largest application segment driven by the established role of HMOs in early-life nutrition. Infant formula represents the largest application segment for human milk oligosaccharides, driven by the established role of HMOs in early-life nutrition and the growing demand for premium infant formula products. HMO-supplemented infant formula products offer a closer nutritional profile to human breast milk, supporting immune development, establishing healthy gut microbiomes, and protecting against infections. Major infant formula manufacturers are increasingly incorporating HMOs into their premium product lines, responding to consumer demand for advanced nutrition. The regulatory approval of HMOs for use in infant formula in major markets, including the European Union, the United States, and Asia Pacific, has accelerated market adoption and product innovation. Dietary supplements represent a growing application segment, with HMO-containing supplements marketed for immune support, digestive health, and overall wellness. The rising consumer awareness of the gut microbiome's role in overall health is driving demand for HMO supplements for adults and children. Functional food and beverages represent an emerging application segment, with manufacturers developing products that incorporate HMOs for gut health benefits. The clean label and natural positioning of HMOs aligns with consumer preferences for functional ingredients derived from natural sources. The others segment includes applications in medical foods, animal nutrition, and cosmetics, representing emerging opportunities for HMO applications beyond human nutrition. The growing body of scientific research on HMO benefits is expanding the addressable market and driving innovation across application segments.

"North America leads the global human milk oligosaccharides market, driven by early regulatory approvals, strong consumer awareness of gut health benefits, and the presence of major infant formula and ingredient companies. North America holds the dominant position in the global HMOs market, with the United States serving as the primary growth engine. The region's leadership is underpinned by early regulatory approvals for HMOs in infant formula and dietary supplements, creating a favorable market environment. The presence of major infant formula manufacturers, ingredient suppliers, and biotechnology companies including Abbott, Mead Johnson, and DuPont, combined with robust research capabilities, drives innovation and product development. The strong consumer awareness of gut health benefits and the growing demand for premium infant nutrition products support market growth. The region's advanced healthcare system and emphasis on early-life nutrition contribute to sustained demand for HMO-containing products. The active consumer wellness culture and growing interest in functional ingredients for health maintenance are expanding the addressable market for HMO supplements and functional foods. Canada follows similar trends with growing adoption of HMO-containing products. The region's combination of regulatory support, consumer awareness, and industry presence ensures continued market leadership through the forecast period. "

In 2025: Major HMO manufacturers expanded production capacity to meet growing demand from infant formula and dietary supplement applications, with investments in fermentation facilities and production efficiency improvements.

In 2025: Regulatory approvals for HMOs expanded to new geographic markets, enabling product launches and market entry in regions with growing demand for premium infant formula.

In 2024: Scientific research on HMO health benefits continued to expand, with studies demonstrating benefits for immune function, gut microbiome modulation, and protection against infections, supporting broader application development.

In 2024: Strategic partnerships and collaborations strengthened the HMO supply chain, with infant formula manufacturers securing long-term supply agreements and ingredient suppliers investing in research and development partnerships.


Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Human Milk Oligosaccharides (HMOs) Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Application
• Dietary Supplements
• Functional Food and Beverages
• Infant Formula
• Others